Caris Life Sciences (CAI) Accumulated Expenses (2024 - 2026)

Caris Life Sciences' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $73.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses changed N/A year-over-year to $73.9 million; the TTM figure through Mar 2026 stood at $73.9 million (changed N/A YoY), while the FY2025 annual figure was $87.8 million, up 13.19% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $73.9 million, down from $87.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $87.8 million in Q4 2025, with the low at $56.9 million in Q3 2025.
• The 3-year median for Accumulated Expenses is $73.9 million (2026), against an average of $71.5 million.
• Peak annual rise in Accumulated Expenses reached 13.19% in 2025, while the deepest fall reached 13.19% in 2025.
• Caris Life Sciences' Accumulated Expenses stood at $77.5 million in 2024, then advanced by 13.19% to $87.8 million in 2025, then slipped by 15.78% to $73.9 million in 2026.
• Business Quant data shows CAI's Accumulated Expenses at $73.9 million in Q1 2026, $87.8 million in Q4 2025, and $56.9 million in Q3 2025.